<DOC>
	<DOCNO>NCT02078219</DOCNO>
	<brief_summary>This study examine hypothesis administration RDEA3170 Japanese patient gout asymptomatic hyperuricemia dose 5 mg , 7.5 mg , 10 mg , 12.5 mg 15 mg daily , respectively result great reduction sUA compare placebo .</brief_summary>
	<brief_title>Phase II Dose Finding Study RDEA3170 Versus Placebo Japanese Patients With Gout Asymptomatic Hyperuricemia</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<criteria>Subject meet follow criterion sUA ≤10.0 mg/dL : 1. sUA level &gt; 7.0 mg/dL 7 day prior baseline gout ; 2. sUA level ≥8.0 mg/dL 7 day prior baseline without gout complication ( hypertension , ischemic heart disease , diabetes , metabolic syndrome ) ; 3. sUA level ≥9.0 mg/dL 7 day prior baseline without gout complication . Subject acute gout flare resolve least 14 day prior baseline visit . Subject history suspicion kidney stone . Subject estimate creatinine clearance &lt; 60 mL/min calculate Cockcroft Gault formula Subject receiving strong moderate CYP3A inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>